[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368080-105":59,"doc-detail-368080-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-assessment-of-a-peptide-vaccine-against-ovarian-cancer-utilizing-nanoliposomes-loaded-with-p53-wt1-and-ca125-epitopes","Development and assessment of a peptide vaccine against ovarian cancer utilizing nanoliposomes loaded with P53, WT1, and CA125 epitopes","","Study designs, synthesizes, and evaluates a multiepitopes peptide vaccine delivered via nanoliposomes (PVNLME) incorporating P53, WT1, and CA125 epitopes. Optimal epitopes are selected bioinformatically, PVNLME is synthesized and characterized, and BALB/c mice receive weekly injections for three weeks at 10 mg/ml or 100 mg/ml. In week four, antibody titers and cytokine profiles are measured, serum is tested against OVCAR3 cells, and BAX/BCL2 expression, viability, and apoptosis are quantified. In humanized PDX model mice, tumor volume is reduced; PVNLME shows 72–198 nm size (mean 112 nm), +30 mV zeta potential, and 96% peptide loading, with dose-dependent immune and pro-apoptotic effects.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-assessment-of-a-peptide-vaccine-against-ovarian-cancer-utilizing-nanoliposomes-loaded-with-p53-wt1-and-ca125-epitopes/368080/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-assessment-of-a-peptide-vaccine-against-ovarian-cancer-utilizing-nanoliposomes-loaded-with-p53-wt1-and-ca125-epitopes/368080.png","ImageObject",300,407,{"name":92,"@type":93},"acoobca","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were epitopes and the peptide formulation selected for the vaccine?","Question",{"text":112,"@type":113},"Optimal epitopes for P53, WT1, and CA125 are selected based on bioinformatics, and a merged multi-epitope peptide is chosen for PVNLME synthesis and characterization.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What animal dosing and assessment schedule was used in the study?",{"text":117,"@type":113},"BALB/c mice were divided into two groups and injected with PVNLME every seven days for three consecutive weeks. In the fourth week, blood samples were collected to measure antibody titers and cytokine levels.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence indicates the vaccine’s effect on ovarian cancer cells and tumors?",{"text":121,"@type":113},"Serum exposure to OVCAR3 cells showed increased BAX/BCL2 expression, reduced cell viability, and increased apoptosis. In humanized PDX mice, administration of the vaccine led to a notable reduction in tumor volume.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368080,1790314349,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Shariati etal. Journal of Ovarian Research (2026) 19:28 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-025-01792-2](https://doi.org/10.1186/s13048-025-01792-2)  \nRESEARCH Open Access  \nDevelopment and assessment of a peptide vaccine against ovarian cancer utilizing nanoliposomes loaded with P53, WT1, and CA125 epitopes  \nFatemeh Shariati1, Mehrdad Hashemi2,3*, Maryam Peyvandi 1, Ali Jebali4 and Maliheh Entezari3  \nAbstract  \nThis study aimed to design, synthesize, and evaluate a peptide vaccine based on nanoliposomes loading multiepitopes (PVNLME) of P53, WT1, and CA125 . We selected the best epitope for each targeted protein and then, PVNLME was synthesized and characterized. Subsequently, BALB/c mice were randomly divided into two groups receiving 10 mg/ml or 100 mg/ml of PVNLME. Then, 100 µl of the vaccine were injected into each mouse every seven days for three consecutive weeks. In the fourth week, blood samples were taken, and both antibody titerand the serum level of different cytokines were measured. To further investigate, each mouse’s serum sample was exposed to the OVCAR3 cell line. Subsequently, BAX to BCL2 gene expression ratio, cell viability, and apoptosis were evaluated. Finally, the efficacy of the peptide vaccine was analyzed in humanized PDX model mice. Based on Bioinformatics analysis, a merged peptide EENLRKKGEPHHELPPKKKKCKTCQRKFSRSDHLKTKKKDTTPSMTTSHGAESSS was selected as a multi-epitope peptide. We found that the size distribution of PVNLME was 72–198 nm with a mean size of 112 nm, zeta potential of + 30 mV, and 96% peptide loading. The level of cytokines and the titer of antibodies increased with increasing doses of PVNLME. Furthermore, we showed that this vaccine can increase the ratio expression of BAX /BCL2, which promotes apoptosis. Also, there was a decrease in cell viability and an increase in apoptosis rate in both doses and exposure times. Following the administration of this multi-epitope vaccine in PDX humanized mice, a notable reduction in the tumor volume was observed.  \nKeywords Multi epitope peptide, Ovarian cancer, Nanoliposomes, P53, WT1, And CA125  \n*Correspondence:  \nMehrdad Hashemi  \n[mhashemi@iau.ac.ir](mhashemi@iau.ac.ir); [drmehhashemi@iautmu.ac.ir](drmehhashemi@iautmu.ac.ir)  \n1Department of Genetics, NT. C, Islamic Azad University, Tehran, Iran 2Department of Genetics, TMS. C, Islamic Azad University, Tehran, Iran 3Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, Faculty of Medicine, TeMs. C., Islamic Azad University, Tehran, Iran  \n4Department of Nanotechnology, TMS. C, Islamic Azad University, Tehran, Iran  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nShariati et al. Journal of Ovarian Research (2026) 19:28  \nIntroduction  \nOvarian cancer ranks as the eighth most prevalent cancer among women worldwide [1]. Ovarian cancer occurs when mutated cells in t","cbCaijPRRyKyJ7Kp","https://ap.wps.com/l/cbCaijPRRyKyJ7Kp","pdf",2950253,"English","# Introduction\n## Ovarian cancer burden and current therapies\n## Immunotherapy and peptide cancer vaccines\n# Materials and Methods\n## Peptide selection and PVNLME synthesis\n## Mouse immunization and sampling schedule\n## In vitro OVCAR3 exposure assays\n## PDX humanized model efficacy testing\n# Results\n## PVNLME characterization and dosing effects\n## Cytokines and antibody responses\n## BAX/BCL2 expression, viability, and apoptosis\n## Tumor volume reduction in PDX models\n# Discussion","[{\"question\":\"How were epitopes and the peptide formulation selected for the vaccine?\",\"answer\":\"Optimal epitopes for P53, WT1, and CA125 are selected based on bioinformatics, and a merged multi-epitope peptide is chosen for PVNLME synthesis and characterization.\"},{\"question\":\"What animal dosing and assessment schedule was used in the study?\",\"answer\":\"BALB/c mice were divided into two groups and injected with PVNLME every seven days for three consecutive weeks. In the fourth week, blood samples were collected to measure antibody titers and cytokine levels.\"},{\"question\":\"What evidence indicates the vaccine’s effect on ovarian cancer cells and tumors?\",\"answer\":\"Serum exposure to OVCAR3 cells showed increased BAX/BCL2 expression, reduced cell viability, and increased apoptosis. In humanized PDX mice, administration of the vaccine led to a notable reduction in tumor volume.\"}]","Development and assessment of a peptide vaccine against ovarian cancer utilizing nanoliposomes loaded with P53, WT1, and CA125 epitopes | PDF",1790174882,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df8fb38aaf0b15be6f8ab0d03ca91e9a.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fa4e847d16babef6f4bafd77481ef32.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f34ad9e294ea76d09f66f40ada5e93bf.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/236e26f44ea2da126697f82c96081050.webp",980,1306]